Aurinia Pharmaceuticals Inc. AUPH

CA Biotechnology

$16.38 ▼ -1.44% ($-0.24)

Open $16.52

Prev Close $16.62

Day Range $16.28 – $16.69

52W Range $13.52 – $19.25

Market Cap $2.23B

P/E (TTM) 6.99

Beta 1.30

EPS (TTM) $2.29

📋 Company Profile

Industry	Biotechnology
Country	CA
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2001-07-16
Shares Out.	134,000,000
Website	auriniapharma.com ↗
Phone	12507442487
Employees	128
Revenue	$83.7M
Gross Profit	$75.4M
Net Income	$31.7M
Free Cash Flow	$177.0M
Total Assets	$825.7M
Total Liabilities	$168.2M
Equity	$657.5M

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Aurinia Pharmaceuticals Inc. is a publicly traded company under the ticker symbol AUPH on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.